India Glycols: How Much Value Can Its Demerger Unlock for Shareholders?
India Glycols’ demerger raises a key question for its investors: can splitting one company into three unlock more value than keeping the businesses together? By separating its spirits and biofuels, specialty chemicals and biopharma operations, the company is giving the market an opportunity to assess each business independently and assign valuations based on its individual strengths.
To understand how much value this restructuring could create, investors must first examine the three entities, the businesses they will operate and the financial performance they bring to the table. This will provide the foundation for estimating their potential valuations and assessing whether the demerger offers a meaningful opportunity for shareholders. With a market cap of Rs 2,200 crore, the shares of India Glycols Ltd are trading at Rs 330 and are trading at a PE of 7 compared to their industry's PE of 46.
Understanding the Three-Way Demerger
The proposed demerger plan by India Glycols Ltd intends to split its diversified business interests into three separate companies which will then be independently traded based on valuations related to each firm’s individual performance, prospects and growth opportunities. The plan received NCLT approval on July 17, 2026, and went ahead on September 1, 2026, with September 2 being set as the cut-off date.
Entity
Business operations
India Glycols Limited
Bio-based specialty materials, sustainable and performance chemicals, and industrial gases
IGL Spirits Limited
Potable spirits, including IMFL and country liquor, along with biofuels
Ennature Bio Pharma Limited
Nutraceuticals, plant-based active pharmaceutical ingredients (APIs), and biopolymers
This corporate split allows each entity to have a focused strategy and optimise capital allocation. Specifically, IGL Spirits will merge both the spirits and the biofuels business segments, thereby taking advantage of the synergy between ethanol manufacturing and consumption within the spirits business. Ennature Bio Pharma will integrate its current biopharma division along with the biopolymers business division that will be spun off from India Glycols. There are also plans to continue benefiting from potential synergies by making appropriate commercial agreements relating to shared resources.
More from the author: Beyond FMCG and Pharma: The Rise of a New Defensive Sector
From an investor perspective, the entitlement ratio forms a key parameter. Shareholders will receive one share of IGL Spirits for each share held in India Glycols, while receiving one share of Ennature Bio Pharma for every three shares held in India Glycols. Thus, an individual who holds 300 shares of India Glycols on the record date will get 300 shares of IGL Spirits and 100 shares of Ennature Bio Pharma.
The demerger creates the opportunity to assess the three businesses separately rather than value them under one corporate structure. However, the separation itself does not guarantee a higher valuation. The extent of value unlocked will depend on the earnings each company generates, its growth prospects and the valuation multiples investors assign once the resulting shares are listed and traded.
Why Has India's Glycols Demerged Its Businesses?
India Glycols demerged its businesses to achieve sharper business focus, improved capital allocation and better visibility of shareholder value. According to its investor presentation, the company aims to create three independently listed businesses, each with its own growth priorities, management focus and resource allocation.
The restructuring separates businesses with different operating models. India Glycols retains bio-based specialty materials, sustainable and performance chemicals, and industrial gases; IGL Spirits houses potable spirits and biofuels; while Ennature Bio Pharma focuses on nutraceuticals, plant-based APIs and biopolymers. The presentation also highlights the transfer of relevant assets, liabilities, contracts and employees to the respective companies, alongside arrangements for shared services.
For shareholders, the key objective is potential value unlocking through independent valuations. In FY26, IGL Spirits contributed Rs 2,801 crore, or approximately 66.5% of the three businesses’ combined net revenue; India Glycols contributed Rs 1,163 crore (27.6%), while Ennature Bio Pharma contributed Rs 247 crore (5.9%). The separation could help investors assess each business according to its individual earnings and industry outlook, although any valuation benefit will depend on future performance and market sentiment.
More from the author: Too Big to Fail, Yet Down Over 30%: Where Could HDFC Bank’s Stock Go After Q2 and a Leadership Reset?
Financial Performance: Which Business Has the Strongest Numbers?
Financial results for India Glycols for FY26 reveal that the spirits business segment is the biggest in terms of both sales and operating income. However, both the specialty chemicals and biopharma business segments present various growth avenues. Both spirits and biofuels leverage scale benefits, and the IGL Spirits business segment has the highest EBITDA among all three segments. The India Glycols segment represents a large-scale business within the specialty chemicals space, while Ennature Bio Pharma is a relatively smaller but rapidly growing entity.
Q1 results for FY27 paint a much better picture of where each business line stands in its trajectory post-reorganisation. IGL Spirits achieved revenues of Rs 694 crores and EBITDA of Rs 120 crores, with its margins improving to 17.3%. India Glycols posted Y-o-Y revenue growth of 24%, while Ennature Bio Pharma grew its revenues by 53% and doubled EBITDA Y-o-Y. The numbers indicate that Spirits business unit is currently the leader on the profitability front, while Ennature Bio Pharma demonstrates rapid revenue growth rates.
Metric
IGL Spirits
India Glycols
Ennature Bio Pharma
FY26 net revenue
Rs 2,801 crore
Rs 1,164 crore
Rs 247 crore
FY26 EBITDA
Rs 492 crore
Rs 169 crore
Rs 29 crore
FY26 EBITDA margin
17.6%
14.5%
11.9%
Q1 FY27 net revenue
Rs 694 crore
Rs 345 crore
Rs 90 crore
Q1 FY27 EBITDA
Rs 120 crore
Rs 40 crore
Rs 10 crore
Q1 FY27 EBITDA margin
17.3%
11.6%
11.1%
Q1 FY27 EBITDA growth (YoY)
17%
12%
100%
The numerical position: Currently, IGL Spirits occupies pole position on both parameters - scale and EBITDA margins. India Glycols has a chemicals business of considerable size, but its margin slipped from that of IGL Spirits in Q1 FY27. Ennature Bio Pharma generates the lowest revenues; however, robust quarterly growth makes the firm worth keeping track of. The critical point for investors is to ascertain whether the growth sustains in the quarters ahead or if the performance was merely a one-off event.
IGL Spirits Listing: What Could Be the Share Price?
The stock price of India Glycols was Rs 1,112.90 on September 1, 2026, compared to the opening of Rs 229.85 on September 2, 2026, after accounting for the effects of the demerger. While a decline of almost 80% sounds alarming, it merely reflects the split-off of two new businesses, its spirits and bio-fuels division and its biopharma subsidiary, rather than a commensurate reduction in the combined worth of the existing shareholders. In exchange for each existing India Glycols share, shareholders received one share each in IGL Spirits and one-third shares each in Ennature Bio Pharma.
One simple way to estimate the value of IGL Spirits is to calculate the difference between the adjusted opening price and the previous day's closing price, yielding an implied total value of Rs 883.05 per India Glycols share prior to demerger. According to figures in the investor presentation, the percentage contribution to revenues was estimated at 67%, 28% and 6%, respectively, for IGL Spirits, the residual India Glycols business, and Ennature Bio Pharma, totalling up to 101%.
Particulars
IGL Spirits
India Glycols
Ennature Bio Pharma
Revenue contribution
67%
28%
6%
Implied value per original share
Rs 586
Rs 245
Rs 52
Share entitlement
1:1
Existing share
1:3
Based on this revenue-based allocation, IGL Spirits accounts for an illustrative value of approximately Rs 586 per share. However, this is not an intrinsic valuation or a reliable estimate of its listing price, as revenue contribution does not necessarily reflect a business's market value. IGL Spirits reported FY26 revenue of Rs 2,801 crore and EBITDA of Rs 492 crore, with an EBITDA margin of 17.6%. Its actual market price will depend on its standalone valuation, net debt, cash flows, comparable-company multiples and investor demand.
Ennature Bio Pharma Listing: How Much Could It Be Worth?
Ennature Bio Pharma is the biopharma and biopolymers segment spun out of India Glycols to create a standalone entity. EnNature’s product line comprises APIs, nutraceuticals and botanical products, offering shareholders a better focus to evaluate its potential within the healthcare and life sciences vertical. The spin-off was implemented from September 1, 2026, onwards, while September 2, 2026, was announced as the cut-off date for deciding the eligibility of shareholders.
More from the author: Augmont Earns 37 Paise on Every ₹100 of Gold. With Import Duty at 15%, How Will the Next Few Quarters Look?
What Could Be Its Estimated Listing Price?
The pre-split closing price of India Glycols stood at Rs 1,112.90, while the opening price of the residual business entity became Rs 229.85 after September 2. This translates into a combined valuation of Rs 883.05 per share for both separated entities post-demerger. Based on the round figures presented in the investor pitch document, which allocates revenues at a ratio of 67%, 28% and 6%, respectively, to IGL Spirits, India Glycols and Ennature, a back-of-envelope calculation suggests a worth of roughly Rs 52 per India Glycols share to be allocated to Ennature.
There are no assurances or guarantees of listing prices or valuations. It is preferable to look at the standalone accounts of Ennature in terms of its profitability, balance sheet strength and cash flow characteristics. Comparisons can then be drawn between pharmaceutical ingredients and nutraceutical players. Ennature generated a net revenue of Rs 90 crore during the quarter ended June 2026.
Sum-of-the-Parts Valuation: What Could Shareholders Gain?
This demerger offers equity investors the ability to separately value the three businesses of India Glycols, which may enhance the clarity regarding their individual valuations. The spirits and biofuels business represents the largest contributor, whereas the residual chemicals business allows access to sustainable materials and specialty chemicals. Finally, Ennature Bio Pharma represents a smaller entity offering access to pharmaceutical ingredients, nutraceuticals and biopolymers.
Some insights emerge upon comparing the FY26 financial performance of these businesses. While IGL Spirits posted Rs 2,801 crore in net revenues and Rs 492 crore in EBITDA, the residual India Glycols business recorded Rs 1,163 crore in net revenues and Rs 169 crore in EBITDA. Ennature Bio Pharma posted Rs 247 crore in net revenues and Rs 29 crore in EBITDA. Such disparity in scale and profitability may result in distinct valuation multiples for each separate entity.
For shareholders, the key question is whether the combined market value of all three businesses will exceed the value attributed to India Glycols before the demerger. A proper sum-of-the-parts valuation must assess each company's earnings, growth prospects, net debt, cash balances and comparable-company multiples. The revenue-based estimates of Rs 586 for IGL Spirits and Rs 52 for Ennature Bio Pharma presented above are illustrative scenarios, not formal fair values or price targets. Investors should compare the companies' actual market prices and financial performance once their shares begin trading independently to determine whether the demerger has unlocked value.
Key Growth Drivers and Risks That Could Affect Valuations
There are distinct differences between the three firms, which relate to growth opportunities. For instance, IGL Spirits can gain from demand for alcoholic beverages and biofuels. Its capacity to manage the product mix and operate efficiently would be vital to generate profits. The residual India Glycols operations revolve around bio-based specialty materials and performance chemicals. Growth would come from expanding into higher-value-added products serving customers looking for alternative sources other than fossil feedstocks. Ennature Bio Pharma needs to scale its APIs, nutraceutical ingredients and biopolymers divisions.
However, the positive indicators are promising but require assessment relative to execution risks. According to figures available for Q1 FY27, IGL Spirits' net revenues were Rs 694 crore and EBITDA Rs 120 crore. Ennature had revenues of Rs 90 crore, representing a year-on-year growth rate of 53%. Its EBITDA stood at Rs 10 crore. The management's FY27 guidance indicated EBITDA margins greater than Rs 500 crore for IGL Spirits and more than Rs 50 crore for Ennature. Please note that those are goals, not guarantees.
More from the author: TARIL: World Bank Overhang, Nuclear Breakthrough and Strong Q2, Can It Make a Comeback?
The main risks include higher raw-material costs, changes in product mix, regulatory requirements and the capital needed to expand capacity. For the chemicals business, demand for specialty products and the ability to sustain margins will be important; for IGL Spirits, premiumisation and expansion into new markets must translate into profitable sales; and for Ennature, rapid revenue growth must be accompanied by stronger margins and consistent execution. Investors should therefore assess whether each business can deliver its targets before assigning it a higher valuation.
The Road Ahead: Can the Demerger Unlock Value for Shareholders?
The demerger allows the three divisions of India Glycols to adopt independent strategies, allocate capital based on their individual priorities, and attract investment by those familiar with their individual industry segments. IGL Spirits will be able to focus exclusively on spirits and biofuels, whereas the remaining business within India Glycols can enhance its standing in the area of bio-materials and specialty chemicals, while Ennature Bio Pharma can concentrate on building out its portfolio of pharmaceutical ingredients, nutraceuticals and biopolymers.
This would mean a more structured approach towards business development, which should facilitate better evaluation of each company's financial results, as opposed to one combined balance sheet and P&L statement. Ultimately, however, success will come down to execution. Each company will have to demonstrate its ability to operate efficiently, control its costs, and convert its strengths into profits.